Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | BCL-2 frontline therapy in CLL

Michael Hallek • 25 Aug 2020
SOHO 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax
CLL17

Michael Hallek, MD, University Hospital of Cologne, Cologne, Germany, explores why BCL-2 inhibition is a superior front-line treatment for patients with chronic lymphocytic leukemia (CLL) and highlights the benefit of combination therapy in CLL therapy, including agents such as venetoclax, obinutuzumab and ibrutinib for this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael Hallek

Updates from the German CLL Study Group
3:53
Updates from the German CLL Study Group
Michael Hallek • 28 Aug 2020
Treating highly relapsed/refractory CLL
3:02
Treating highly relapsed/refractory CLL
Michael Hallek • 27 Aug 2020
Value of MRD measurement in CLL
2:32
Value of MRD measurement in CLL
Michael Hallek • 27 Aug 2020
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
1:17
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Michael Hallek • 19 Jun 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals